NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination

  • Marcus Ruscetti
  • , Josef Leibold
  • , Matthew J. Bott
  • , Myles Fennell
  • , Amanda Kulick
  • , Nelson R. Salgado
  • , Chi Chao Chen
  • , Yu jui Ho
  • , Francisco J. Sanchez-Rivera
  • , Judith Feucht
  • , Timour Baslan
  • , Sha Tian
  • , Hsuan An Chen
  • , Paul B. Romesser
  • , John T. Poirier
  • , Charles M. Rudin
  • , Elisa De Stanchina
  • , Eusebio Manchado
  • , Charles J. Sherr
  • , Scott W. Lowe

Research output: Contribution to journalArticlepeer-review

335 Scopus citations

Abstract

Molecularly targeted therapies aim to obstruct cell autonomous programs required for tumor growth. We show that mitogen-activated protein kinase (MAPK) and cyclin-dependent kinase 4/6 inhibitors act in combination to suppress the proliferation of KRAS-mutant lung cancer cells while simultaneously provoking a natural killer (NK) cell surveillance program leading to tumor cell death. The drug combination, but neither agent alone, promotes retinoblastoma (RB) protein-mediated cellular senescence and activation of the immunomodulatory senescence-associated secretory phenotype (SASP). SASP components tumor necrosis factor–a and intercellular adhesion molecule–1 are required for NK cell surveillance of drug-treated tumor cells, which contributes to tumor regressions and prolonged survival in a KRAS-mutant lung cancer mouse model. Therefore, molecularly targeted agents capable of inducing senescence can produce tumor control through non–cell autonomous mechanisms involving NK cell surveillance.

Original languageEnglish
Pages (from-to)1416-1422
Number of pages7
JournalScience
Volume362
Issue number6421
DOIs
StatePublished - Dec 21 2018
Externally publishedYes

Fingerprint

Dive into the research topics of 'NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination'. Together they form a unique fingerprint.

Cite this